206 related articles for article (PubMed ID: 37459541)
1. Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response.
Qiao Y; Wotring JW; Zheng Y; Zhang CJ; Zhang Y; Jiang X; Pretto CD; Eyunni S; Parolia A; He T; Cheng C; Cao X; Wang R; Su F; Ellison SJ; Wang Y; Qin J; Yan H; Zhou Q; Ma L; Sexton JZ; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2023 Jul; 120(30):e2221809120. PubMed ID: 37459541
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 and androgen-targeted therapy for prostate cancer patients.
Bhowmick NA; Oft J; Dorff T; Pal S; Agarwal N; Figlin RA; Posadas EM; Freedland SJ; Gong J
Endocr Relat Cancer; 2020 Sep; 27(9):R281-R292. PubMed ID: 32508311
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS).
Cadegiani FA; Goren A; Wambier CG
Med Hypotheses; 2020 Oct; 143():110112. PubMed ID: 32721806
[TBL] [Abstract][Full Text] [Related]
4. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial.
Cadegiani FA; McCoy J; Gustavo Wambier C; Vaño-Galván S; Shapiro J; Tosti A; Zimerman RA; Goren A
Cureus; 2021 Feb; 13(2):e13492. PubMed ID: 33633920
[TBL] [Abstract][Full Text] [Related]
5. Do Anti-androgens Have Potential as Therapeutics for COVID-19?
Mauvais-Jarvis F
Endocrinology; 2021 Aug; 162(8):. PubMed ID: 34089595
[TBL] [Abstract][Full Text] [Related]
6. Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide.
Li F; Han M; Dai P; Xu W; He J; Tao X; Wu Y; Tong X; Xia X; Guo W; Zhou Y; Li Y; Zhu Y; Zhang X; Liu Z; Aji R; Cai X; Li Y; Qu D; Chen Y; Jiang S; Wang Q; Ji H; Xie Y; Sun Y; Lu L; Gao D
Nat Commun; 2021 Feb; 12(1):866. PubMed ID: 33558541
[TBL] [Abstract][Full Text] [Related]
7. Apalutamide Prevents SARS-CoV-2 Infection in Lung Epithelial Cells and in Human Nasal Epithelial Cells.
Majidipur A; Morin-Dewaele M; Gaspar Lopes J; Berry F; Fouchet J; Bartier S; Dufros Duval A; Soyeux P; Huet E; Louis B; Coste A; Béquignon É; Saldana C; Le Corvoisier P; Destouches D; Pawlotsky JM; de la Taille A; Vacherot F; Bruscella P; Firlej V
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834705
[TBL] [Abstract][Full Text] [Related]
8. Association between SARS-CoV-2 infection and disease severity among prostate cancer patients on androgen deprivation therapy: a systematic review and meta-analysis.
Sari Motlagh R; Abufaraj M; Karakiewicz PI; Rajwa P; Mori K; Mun DH; Shariat SF
World J Urol; 2022 Apr; 40(4):907-914. PubMed ID: 34477955
[TBL] [Abstract][Full Text] [Related]
9. A Novel Glucocorticoid and Androgen Receptor Modulator Reduces Viral Entry and Innate Immune Inflammatory Responses in the Syrian Hamster Model of SARS-CoV-2 Infection.
Rocha SM; Fagre AC; Latham AS; Cummings JE; Aboellail TA; Reigan P; Aldaz DA; McDermott CP; Popichak KA; Kading RC; Schountz T; Theise ND; Slayden RA; Tjalkens RB
Front Immunol; 2022; 13():811430. PubMed ID: 35250984
[TBL] [Abstract][Full Text] [Related]
10. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).
Montopoli M; Zumerle S; Vettor R; Rugge M; Zorzi M; Catapano CV; Carbone GM; Cavalli A; Pagano F; Ragazzi E; Prayer-Galetti T; Alimonti A
Ann Oncol; 2020 Aug; 31(8):1040-1045. PubMed ID: 32387456
[TBL] [Abstract][Full Text] [Related]
11. Novel Strategy of Proxalutamide for the Treatment of Prostate Cancer through Coordinated Blockade of Lipogenesis and Androgen Receptor Axis.
Gu Y; Xue M; Wang Q; Hong X; Wang X; Zhou F; Sun J; Wang G; Peng Y
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948018
[No Abstract] [Full Text] [Related]
12. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
[TBL] [Abstract][Full Text] [Related]
13. Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2.
Klein EA; Li J; Milinovich A; Schold JD; Sharifi N; Kattan MW; Jehi L
J Urol; 2021 Feb; 205(2):441-443. PubMed ID: 32897764
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of two potential novel SARS-CoV-2 entries, TMPRSS2 and IFITM3, in healthy individuals and cancer patients.
Dai YJ; Zhang WN; Wang WD; He SY; Liang CC; Wang DW
Int J Biol Sci; 2020; 16(15):3028-3036. PubMed ID: 33061814
[TBL] [Abstract][Full Text] [Related]
15. The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells.
Leach DA; Mohr A; Giotis ES; Cil E; Isac AM; Yates LL; Barclay WS; Zwacka RM; Bevan CL; Brooke GN
Nat Commun; 2021 Jul; 12(1):4068. PubMed ID: 34210968
[TBL] [Abstract][Full Text] [Related]
16. Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial.
Cadegiani FA; Zimerman RA; Fonseca DN; Correia MN; Muller MP; Bet DL; Slaviero MR; Zardo I; Benites PR; Barros RN; Paulain RW; Onety DC; Israel KCP; Gustavo Wambier C; Goren A
Cureus; 2021 Dec; 13(12):e20691. PubMed ID: 34976549
[TBL] [Abstract][Full Text] [Related]
17. Targeting transcriptional regulation of SARS-CoV-2 entry factors
Qiao Y; Wang XM; Mannan R; Pitchiaya S; Zhang Y; Wotring JW; Xiao L; Robinson DR; Wu YM; Tien JC; Cao X; Simko SA; Apel IJ; Bawa P; Kregel S; Narayanan SP; Raskind G; Ellison SJ; Parolia A; Zelenka-Wang S; McMurry L; Su F; Wang R; Cheng Y; Delekta AD; Mei Z; Pretto CD; Wang S; Mehra R; Sexton JZ; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2021 Jan; 118(1):e2021450118. PubMed ID: 33310900
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiological conditions induced by SARS-CoV-2 infection reduce ACE2 expression in the lung.
Miura Y; Ohkubo H; Nakano A; Bourke JE; Kanazawa S
Front Immunol; 2022; 13():1028613. PubMed ID: 36405683
[TBL] [Abstract][Full Text] [Related]
19. Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients.
Giotis ES; Cil E; Brooke GN
Viruses; 2022 Dec; 14(12):. PubMed ID: 36560732
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy in men with prostate cancer is not associated with COVID-2019 infection.
Davidsson S; Messing Eriksson A; Udumyan R; Swanholm P; Lewin Lundh M; Widing C; Lindlöf C; Fridfeldt J; Andersson SO; Fall K
Prostate; 2023 May; 83(6):555-562. PubMed ID: 36658755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
